Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by Leguay et al

被引：0
|
作者：
R G Piazza
V Magistroni
A Franceschino
C Gambacorti-Passerini
机构：
[1] S. Gerardo Hospital,Department of Oncology
[2] University of Milano Bicocca,undefined
[3] Section of Hematology,undefined
[4] S. Gerardo Hospital,undefined
[5] McGill University,undefined
来源：
Leukemia | 2005年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2333 / 2334
页数：1
相关论文
共 24 条
  • [1] Response to 'D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients' by Leguay et al
    Piazza, RG
    Magistroni, V
    Franceschino, A
    Gambacorti-Passerini, C
    LEUKEMIA, 2005, 19 (12) : 2333 - 2334
  • [2] D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients
    Leguay, T
    Desplat, V
    Marit, G
    Mahon, FX
    LEUKEMIA, 2005, 19 (12) : 2332 - 2333
  • [3] D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients
    T Leguay
    V Desplat
    G Marit
    F-X Mahon
    Leukemia, 2005, 19 : 2332 - 2333
  • [4] Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response
    Osorio, S.
    Noblejas, A. Garcia
    Duran, A.
    Steegmann, J. L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (05) : 394 - 395
  • [5] Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation
    Nicolini, Franck E.
    Hayette, Sandrine
    Corm, Selim
    Bachy, Emmanuel
    Bories, Dominique
    Tulliez, Michel
    Guilhot, Francois
    Legros, Laurence
    Maloisel, Frederic
    Kiladjian, Jean-Jacques
    Mahon, Francois-Xavier
    Quoc-Hung Le
    Michallet, Mauricette
    Roche-Lestienne, Catherine
    Preudhomme, Claude
    HAEMATOLOGICA, 2007, 92 (09) : 1238 - 1241
  • [6] Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia - Cancer and leukemia group B study 10107
    Wetzler, Meir
    Donohue, Kathleen A.
    Odenike, Olatoyosi M.
    Feldman, Eric J.
    Hurd, David D.
    Stone, Richard M.
    Westerfelt, Peter
    Bloomfield, Clara D.
    Larson, Richard A.
    LEUKEMIA & LYMPHOMA, 2008, 49 (07) : 1274 - 1278
  • [7] Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients:: a retrospective analysis from the French intergroup of CML (Fi(φ)-LMC GROUP)
    Nicolini, F. E.
    Corm, S.
    Le, Q. -H.
    Sorel, N.
    Hayette, S.
    Bories, D.
    Leguay, T.
    Roy, L.
    Giraudier, S.
    Tulliez, M.
    Facon, T.
    Mahon, F. -X.
    Cayuela, J. -M.
    Rousselot, P.
    Michallet, M.
    Preudhomme, C.
    Guilhot, F.
    Roche-Lestienne, C.
    LEUKEMIA, 2006, 20 (06) : 1061 - 1066
  • [8] Clinical outcome of 40 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a M351T BCR-ABL kinase domain mutation
    Mir, Ab Rashid
    FASEB JOURNAL, 2009, 23
  • [9] Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy
    Lippert, Eric
    Etienne, Gabriel
    Mozziconacci, Marie-Joelle
    Laibe, Sophy
    Gervais, Carine
    Girault, Stephane
    Gachard, Nathalie
    Tigaud, Isabelle
    Dastugue, Nicole
    Huguet, Francois
    Fort, Marie-Pierre
    Legros, Laurence
    Eclache, Virginie
    Mahon, Francois-Xavier
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (09): : 1604 - 1607
  • [10] Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)
    F E Nicolini
    S Corm
    Q-H Lê
    N Sorel
    S Hayette
    D Bories
    T Leguay
    L Roy
    S Giraudier
    M Tulliez
    T Facon
    F-X Mahon
    J-M Cayuela
    P Rousselot
    M Michallet
    C Preudhomme
    F Guilhot
    C Roche-Lestienne
    Leukemia, 2006, 20 : 1061 - 1066
123